Equity Profile

RCUS

Arcus Biosciences, Inc.

Health CareBiotechnology$3.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Arcus Biosciences, Inc. (RCUS) is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs relative to its revenue.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and validate its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RCUS Q2-2026 Earnings Preview

Context

Company Snapshot

Arcus Biosciences, Inc. (RCUS) is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $4 billion, it operates in the health care sector, which is currently seeing significant advancements in personalized medicine and immunotherapy.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.06%

Avg Stock Reaction

-0.13%

Last Quarter Recap

In Q1-2026, Arcus reported an EPS of -$1.02, missing expectations by 10.87%. The stock saw a slight increase of 0.04% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Continued focus on advancing clinical trials for its lead therapies.
Commitment to managing operational costs effectively.
Plans to provide more detailed updates on pipeline progress in future calls.

Expectations

Wall Street Expectations

Overall, expectations for Arcus's upcoming earnings are cautious, given the recent EPS misses and lack of revenue guidance.

Bull Case

If Arcus can demonstrate significant progress in its clinical trials and manage costs effectively, it could lead to a positive surprise and boost investor confidence.

Bear Case

Conversely, if the company fails to provide clear updates on its pipeline or reports larger-than-expected losses, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of clinical trials?

Investors will closely watch for any advancements or setbacks in clinical trials, as these can significantly impact the company's future prospects.

How is the company managing its operational costs in light of recent losses?

Effective cost management is crucial for sustainability, especially as the company continues to invest in its product pipeline.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of recent clinical trial results, which could show more promise than anticipated.

Supporting Evidence

The options market is pricing a 33.5% move, indicating expectations of volatility that may not align with the actual outcomes.

The company's strong track record of beating EPS estimates (75% success rate) suggests it could surprise the market positively.

Key Risk

If clinical trial updates indicate significant progress, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to advance its clinical pipeline while managing costs effectively.

Bull Confirmed If

A clear update on clinical trial progress that shows positive results could confirm the bull case.

Bear Confirmed If

A larger-than-expected loss or lack of clarity on future trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±33.5%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect high volatility around the earnings report.

Options are pricing ±33.5% while RCUS has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

56.4%

Calls (400)P/C Ratio: 0.40Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcus beats expectations and raises guidance, history suggests a positive reaction, with an average 1-day move of +1.35%.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction, reflecting uncertainty.

Miss

A miss could lead to a negative reaction, with history suggesting an average 1-day move of -4.57%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific timelines for upcoming clinical trial results.
2Updates on partnerships or collaborations that could enhance their pipeline.
3Details on cost management strategies moving forward.
4Any changes in regulatory environment affecting their products.
5Insights into market demand for their therapies based on recent trends.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Arcus Biosciences, Inc. (RCUS) is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs relative to its revenue.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and validate its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RCUS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.06%

Avg Stock Reaction

-0.13%

Last Quarter Recap

In Q1-2026, Arcus reported an EPS of -$1.02, missing expectations by 10.87%. The stock saw a slight increase of 0.04% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Continued focus on advancing clinical trials for its lead therapies.
Commitment to managing operational costs effectively.
Plans to provide more detailed updates on pipeline progress in future calls.

Expectations

Wall Street Expectations

Overall, expectations for Arcus's upcoming earnings are cautious, given the recent EPS misses and lack of revenue guidance.

Bull Case

If Arcus can demonstrate significant progress in its clinical trials and manage costs effectively, it could lead to a positive surprise and boost investor confidence.

Bear Case

Conversely, if the company fails to provide clear updates on its pipeline or reports larger-than-expected losses, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of clinical trials?

Investors will closely watch for any advancements or setbacks in clinical trials, as these can significantly impact the company's future prospects.

How is the company managing its operational costs in light of recent losses?

Effective cost management is crucial for sustainability, especially as the company continues to invest in its product pipeline.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of recent clinical trial results, which could show more promise than anticipated.

Supporting Evidence

The options market is pricing a 33.5% move, indicating expectations of volatility that may not align with the actual outcomes.

The company's strong track record of beating EPS estimates (75% success rate) suggests it could surprise the market positively.

Key Risk

If clinical trial updates indicate significant progress, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to advance its clinical pipeline while managing costs effectively.

Bull Confirmed If

A clear update on clinical trial progress that shows positive results could confirm the bull case.

Bear Confirmed If

A larger-than-expected loss or lack of clarity on future trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±33.5%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect high volatility around the earnings report.

Options are pricing ±33.5% while RCUS has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

56.4%

Calls (400)P/C Ratio: 0.40Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcus beats expectations and raises guidance, history suggests a positive reaction, with an average 1-day move of +1.35%.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction, reflecting uncertainty.

Miss

A miss could lead to a negative reaction, with history suggesting an average 1-day move of -4.57%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific timelines for upcoming clinical trial results.
2Updates on partnerships or collaborations that could enhance their pipeline.
3Details on cost management strategies moving forward.
4Any changes in regulatory environment affecting their products.
5Insights into market demand for their therapies based on recent trends.